Loading...

Haleon plc

HLN•NYSE
HealthcareDrug Manufacturers - Specialty & Generic
$10.45
$-0.26(-2.43%)

Haleon plc (HLN) Stock Overview

Explore Haleon plc’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-0.61%
↓ 0.61%
Profit Growth
$0.16
↑ 37.46%
EPS Growth
$0.16
↑ 45.45%
Operating Margin
19.70%
↑ 10.52%
ROE
8.71%
↑ 37.46%
Dividend Yield
0.00%
↑ 49.43%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
3
Sell
0
Strong Sell
0

Price Targets

Low$10.20
Average$10.20
High$10.20

Company Profile

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

CEO

Mr. Brian James McNamara

Employees

24,561

Headquarters

Building 5, Weybridge

Founded

2022

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.